SCNI — Scinai Immunotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- $0.13m
- $15.02m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | 10-K | 20-F |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | fx Final | fx Final | fx Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 22 | -2.13 | 10.8 | 11.1 | 9.71 |
Operating Profit | -22 | 2.13 | -10.8 | -11.1 | -9.71 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -30.7 | -1.3 | -12.4 | -5.8 | -6.5 |
Net Income After Taxes | -30.7 | -1.3 | -12.4 | -5.8 | -6.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.7 | -1.3 | -12.4 | -5.8 | -6.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.7 | -1.3 | -12.4 | -5.8 | -6.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -9.39 | -0.292 | -2.19 | -0.077 | -0.042 |